Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
What happened in 'Wicked' part 1 and will there be a 3rd movie? Recap and what Ariana Grande, Jon M. Chu have said about a sequel. - 2The Response Uncovered: Disentangling the Secrets of the Universe
- 3Where is Santa right now? NORAD tracks his 2025 Christmas Eve flight.
- 4Watching ‘Home Alone’ with the kids this holiday season? Brace yourself for '6-7.'
- 5Don't plan to cook on Thanksgiving? Here are the restaurants and fast food places that are scheduled to be open
- Vote in favor of the handheld vacuum that you love for its strong attractions!
- The Meaning of Breaking the Pen's Nib in Death penalties
- A Russian fighting for Ukraine conned the Kremlin out of $500,000 by faking his own death
- Venice’s newest marvel is a wild, acrobatic dolphin. His refusal to leave puts him in danger
- The Most Well known Online Entertainment Forces to be reckoned with of 2023
- 80 km. on foot: Sharren Haskel’s three-day march in protest of haredi draft bill
- New movies to watch this week: See 'Marty Supreme' in theaters, rent 'Springsteen: Deliver Me from Nowhere,' stream 'Cover-Up' on Netflix
- Step by step instructions to Pick the Ideal Authorize Internet Advertising Degree Program
- Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial
